Scientific poster: Advantage of antibody based selectivity in the purification of biologics
Posted: 26 June 2019 | Thermo Fisher Scientific | No comments yet
ADVANCES in biotherapeutics are generating an increasing range of complex molecules that present unique and often complex purification challenges.
By taking advantage of antibody based selectivity, Camelid heavy-chain antibody fragments (VHHs) have proven to be a reliable immunoaffinity chromatography (IAC) solution in the downstream process of biologics. ThermoScientific™ CaptureSelect™ affinity products and analytical tools are developed for the discovery and manufacturing of even the most demanding biotherapeutics.
Related content from this organisation
- The opportunities for CDMOs in the pharmaceutical industry
- Thermo Fisher Scientific to acquire QIAGEN for $11.5bn
- Application note: Biologic drug identification at fill and finish
- Application Notes & Whitepapers 2019
- Increased raw material verification capabilities with portable Raman and XRF instruments
Related topics
Analytical techniques, Antibodies, Biologics, Bioproduction, Drug Discovery, Drug Manufacturing
